Among the newly discovered potential biomarkers in HCC, AFP-L3 (a glycoform of alpha-fetoprotein, AFP) is recently approved by FDA as as a supplemental test in patients with elevated total AFP. Here, AFP is linked to hepatocellular carcinoma.